Corcept Therapeutics Inc [CORT] stock is trading at $83.67, up 3.60%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CORT shares have gain 4.22% over the last week, with a monthly amount glided 12.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Truist upgraded its rating to Buy on November 06, 2023, and elevated its price target to $38. On April 11, 2023, SVB Securities initiated with a Market Perform rating and assigned a price target of $25 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $27 on April 04, 2023. Jefferies downgraded its rating to a Hold and reduced its price target to $22 on February 15, 2023. Truist downgraded its rating to Hold for this stock on August 01, 2022, but kept the price target unchanged to $30. In a note dated July 27, 2022, Jefferies upgraded an Buy rating on this stock and boosted its target price from $21 to $35.
Corcept Therapeutics Inc [CORT] stock has fluctuated between $49.00 and $117.33 over the past year. Currently, Wall Street analysts expect the stock to reach $140 within the next 12 months. Corcept Therapeutics Inc [NASDAQ: CORT] shares were valued at $83.67 at the most recent close of the market. An investor can expect a potential return of 67.32% based on the average CORT price forecast.
Analyzing the CORT fundamentals
Corcept Therapeutics Inc [NASDAQ:CORT] reported sales of 741.17M for the trailing twelve months, which represents a growth of 13.75%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.13, Equity is 0.16 and Total Capital is 0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 81.51 points at the first support level, and at 79.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 85.15, and for the 2nd resistance point, it is at 86.63.
Ratios To Look Out For
For context, Corcept Therapeutics Inc’s Current Ratio is 3.14. Further, the Quick Ratio stands at 3.07, while the Cash Ratio is 0.73. Considering the valuation of this stock, the price to sales ratio is 11.87, the price to book ratio is 13.92 and price to earnings (TTM) ratio is 95.60.
Transactions by insiders
Recent insider trading involved Guyer William, Chief Development Officer, that happened on Dec 02 ’25 when 20000.0 shares were sold. See Remarks, Maduck Sean completed a deal on Dec 01 ’25 to sell 20000.0 shares. Meanwhile, See Remarks Lyon Joseph Douglas sold 5000.0 shares on Dec 01 ’25.
